Pharmaceutical

Palleon and Shanghai Henlius Biotech link on autoimmune therapy

Palleon and Henlius Biotech have entered into a licence agreement and partnership for the former’s E-602 to treat autoimmune diseases.

Dec 21, 2024 - 06:00
Palleon and Shanghai Henlius Biotech link on autoimmune therapy
Palleon and Henlius Biotech have entered into a licence agreement and partnership for the former’s E-602 to treat autoimmune diseases.
Read the original article

Tags:

Previous Article

Setback for UK pharma as government sets unexpectedly high VPAG payback rate in ...

Next Article

Astellas and Sangamo sign capsid deal for neurological diseases

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bird flu researchers turn to Finland’s mink farms, tracking a virus with pandemic potential

Bird flu researchers turn to Finland’s mink farms, trac...

Aug 11, 2023

STAT+: 1 in 5 primary endpoints changed in late-stage trials of cancer drugs already underway, study finds

STAT+: 1 in 5 primary endpoints changed in late-stage t...

May 19, 2023

Idorsia introduces Quviviq in Switzerland for chronic insomnia treatment

Idorsia introduces Quviviq in Switzerland for chronic i...

Jun 13, 2023